KR102924294B1 - 아졸-융합된 피리다진-3(2h)-온 유도체 - Google Patents

아졸-융합된 피리다진-3(2h)-온 유도체

Info

Publication number
KR102924294B1
KR102924294B1 KR1020227012292A KR20227012292A KR102924294B1 KR 102924294 B1 KR102924294 B1 KR 102924294B1 KR 1020227012292 A KR1020227012292 A KR 1020227012292A KR 20227012292 A KR20227012292 A KR 20227012292A KR 102924294 B1 KR102924294 B1 KR 102924294B1
Authority
KR
South Korea
Prior art keywords
pyridazin
ethyl
dihydro
acetamide
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227012292A
Other languages
English (en)
Korean (ko)
Other versions
KR20220063228A (ko
Inventor
홀거 모넨샤인
숀 머피
스콧 올슨
나타샤 오루크
홀리 라이차드
멜린다 데이비스
베티 램
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20220063228A publication Critical patent/KR20220063228A/ko
Application granted granted Critical
Publication of KR102924294B1 publication Critical patent/KR102924294B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227012292A 2019-09-16 2020-09-15 아졸-융합된 피리다진-3(2h)-온 유도체 Active KR102924294B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901052P 2019-09-16 2019-09-16
US62/901,052 2019-09-16
PCT/US2020/050823 WO2021055326A1 (en) 2019-09-16 2020-09-15 Azole-fused pyridazin-3(2h)-one derivatives

Publications (2)

Publication Number Publication Date
KR20220063228A KR20220063228A (ko) 2022-05-17
KR102924294B1 true KR102924294B1 (ko) 2026-02-09

Family

ID=72670806

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012292A Active KR102924294B1 (ko) 2019-09-16 2020-09-15 아졸-융합된 피리다진-3(2h)-온 유도체

Country Status (25)

Country Link
US (1) US12370192B2 (enExample)
EP (1) EP4031552B1 (enExample)
JP (1) JP7566888B2 (enExample)
KR (1) KR102924294B1 (enExample)
CN (1) CN114728975A (enExample)
AR (1) AR119971A1 (enExample)
AU (1) AU2020348675B2 (enExample)
BR (1) BR112022004819A2 (enExample)
CA (1) CA3150508A1 (enExample)
CO (1) CO2022004684A2 (enExample)
CR (1) CR20220160A (enExample)
DO (1) DOP2022000057A (enExample)
EC (1) ECSP22020159A (enExample)
ES (1) ES2997267T3 (enExample)
HR (1) HRP20250088T1 (enExample)
HU (1) HUE069908T2 (enExample)
IL (1) IL291181B2 (enExample)
JO (1) JOP20220063A1 (enExample)
MX (1) MX2022003177A (enExample)
PE (1) PE20221341A1 (enExample)
PH (1) PH12022550597A1 (enExample)
PL (1) PL4031552T3 (enExample)
RS (1) RS66463B1 (enExample)
TW (1) TWI873185B (enExample)
WO (1) WO2021055326A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
PL4031552T3 (pl) 2019-09-16 2025-03-17 Takeda Pharmaceutical Company Limited Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów
JP7697974B2 (ja) 2020-05-08 2025-06-24 武田薬品工業株式会社 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds
CN114149371B (zh) * 2021-11-26 2023-08-22 首都医科大学 四取代吡唑类化合物及其应用
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
US20250163065A1 (en) * 2022-03-01 2025-05-22 Shanghaitech University Pyrrolotriazinone compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3
CN116063179A (zh) * 2023-02-20 2023-05-05 南京杰运医药科技有限公司 一种4-甲氧基乙酰乙酸甲酯的合成方法
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
WO2025124544A1 (zh) * 2023-12-14 2025-06-19 华润医药研究院（深圳）有限公司 3,4-二氢-2H-苯并[b][1,4]二氧杂环庚烷类化合物及其制备方法和医药用途
WO2025162441A1 (zh) * 2024-02-02 2025-08-07 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP2017535559A (ja) 2014-11-20 2017-11-30 武田薬品工業株式会社 Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0799617A3 (en) 1986-02-24 1997-11-12 Mitsui Petrochemical Industries, Ltd. Therapeutic agent for neurological diseases
EP0315390B1 (en) 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
JPH0285851A (ja) 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP2874960B2 (ja) 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE4339868A1 (de) * 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2320354A1 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
EP1235572A2 (en) 1999-10-29 2002-09-04 MERCK SHARP & DOHME LTD. Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
JP2003526341A (ja) 1999-11-04 2003-09-09 コロラド ステート ユニバーシティー リサーチ ファウンデーション 昆虫を誘引するための装置および方法
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002085851A (ja) 2000-09-19 2002-03-26 Totan Information Technology Kk 経済指標予想ゲームシステム
EP1436270A1 (en) 2001-10-10 2004-07-14 Neurosearch A/S Novel benzothiazine derivatives, their preparation and use
FR2833955B1 (fr) 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003091242A1 (en) 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, process for producing the same and use thereof
JP4079727B2 (ja) 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JP3981316B2 (ja) 2002-09-27 2007-09-26 京セラ株式会社 半導体素子収納用パッケージ
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
CA2533824A1 (en) 2003-07-31 2005-02-10 Irm, Llc Bicyclic compounds and compositions as pdf inhibitors
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
FR2879201B1 (fr) 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4738988B2 (ja) 2005-11-17 2011-08-03 花王株式会社 ２連式吐出器
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EP2040551A4 (en) 2006-06-23 2010-02-17 Nufarm Australia Ltd HERBIC PHENOXYALKANOATE COMPOSITION AND METHOD FOR THE PRODUCTION AND USE THEREOF
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
US8097652B2 (en) 2006-12-11 2012-01-17 Eli Lilly And Company AMPA receptor potentiators
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
WO2008089005A2 (en) 2007-01-12 2008-07-24 Takeda Pharmaceutical Company Limited Renin inhibitors
EP2108017A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
EP2217604A1 (en) 2007-11-05 2010-08-18 Schering Corporation Gamma secretase modulators
JP2009119088A (ja) 2007-11-16 2009-06-04 Hoya Corp 内視鏡用バイポーラ高周波処置具
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101981034B (zh) 2008-02-05 2013-08-14 赛诺菲-安万特 作为par1抑制剂的三唑并哒嗪、其制备及其制备药物的用途
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
JP2009248543A (ja) 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
FR2933698A1 (fr) 2008-07-09 2010-01-15 Servier Lab Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2742317A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (ja) 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
US20120142672A1 (en) 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
SI2603513T1 (sl) 2010-08-10 2020-07-31 Takeda Pharmaceutical Company Limited Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator receptorja AMPA
US20140336216A1 (en) 2013-03-14 2014-11-13 Janssen Pharmaceutica Nv Physiological ligands for gpr139
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
CN118684633A (zh) 2018-10-18 2024-09-24 埃萨制药股份有限公司 雄激素受体调节剂及其使用方法
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
EP3947353A4 (en) 2019-03-28 2023-07-05 Essa Pharma, Inc. PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS WITH ANDROGEN RECEPTOR INHIBITORS AND THEIR USES
PL4031552T3 (pl) 2019-09-16 2025-03-17 Takeda Pharmaceutical Company Limited Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów
BR112022003514A2 (pt) 2019-09-16 2022-05-17 Novartis Ag Degradadores bifuncionais de brd9 e seus métodos de uso
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
JP7697974B2 (ja) 2020-05-08 2025-06-24 武田薬品工業株式会社 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
TW202227087A (zh) 2020-09-21 2022-07-16 日商武田藥品工業股份有限公司 精神分裂症之治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
JP2017535559A (ja) 2014-11-20 2017-11-30 武田薬品工業株式会社 Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン

Also Published As

Publication number Publication date
IL291181A (en) 2022-05-01
AU2020348675A1 (en) 2022-04-14
CR20220160A (es) 2022-06-16
JOP20220063A1 (ar) 2023-01-30
JP2022548602A (ja) 2022-11-21
US12370192B2 (en) 2025-07-29
EP4031552B1 (en) 2024-11-06
DOP2022000057A (es) 2022-06-30
MX2022003177A (es) 2022-04-06
IL291181B1 (en) 2025-05-01
EP4031552A1 (en) 2022-07-27
KR20220063228A (ko) 2022-05-17
US20230028114A1 (en) 2023-01-26
BR112022004819A2 (pt) 2022-06-07
HRP20250088T1 (hr) 2025-03-28
WO2021055326A1 (en) 2021-03-25
AU2020348675B2 (en) 2025-11-20
PL4031552T3 (pl) 2025-03-17
IL291181B2 (en) 2025-09-01
TWI873185B (zh) 2025-02-21
ES2997267T3 (en) 2025-02-14
CO2022004684A2 (es) 2022-07-08
ECSP22020159A (es) 2022-05-31
JP7566888B2 (ja) 2024-10-15
HUE069908T2 (hu) 2025-04-28
RS66463B1 (sr) 2025-02-28
CA3150508A1 (en) 2021-03-25
TW202124386A (zh) 2021-07-01
EP4031552C0 (en) 2024-11-06
PH12022550597A1 (en) 2024-03-04
AR119971A1 (es) 2022-01-26
PE20221341A1 (es) 2022-09-13
CN114728975A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
US12247015B2 (en) 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
CA2832291C (en) Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
EP2909212B1 (en) Substituted 1,4-dihydropyrazolo[4,3-b]indoles
WO2013130855A1 (en) Indazole derivatives
JP2016540811A (ja) Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
EP4504733A1 (en) Fused pyridazine derivatives as nlrp3 inhibitors
EA053259B1 (ru) Конденсированные с азолом производные пиридазин-3(2н)-она
HK40076219B (en) Azole-fused pyridazin-3(2h)-one derivatives
HK40076219A (en) Azole-fused pyridazin-3(2h)-one derivatives
CA3137584C (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)